Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Allotera Therapeutics closes a $35 million funding round to advance off-the-shelf CAR-T therapies for T-cell cancers, aiming to enhance clinical development and manufacturing.
PRIVATEJul 08, 2026•19 days ago
Amount Raised
$35 Million
Round Type
Funding Round
Saint LouisBiotechnologyHealth CareTherapeutics
Description
Allotera Therapeutics has successfully closed a $35 million financing round comprised of equity and venture debt. The funding will support the global pivotal T-RRex clinical trial of their therapy, Sofi-cel, for T-cell cancers. This round brings the total capital raised by Allotera to $150 million. The company's new name reflects its commitment to developing vital therapies for patients with limited treatment options.
Company Information
Company
Allotera Therapeutics
Location
Saint Louis, Missouri, United States
About
Allotera Therapeutics, Inc. (formerly Wugen, Inc.) is a clinical-stage biotechnology company that specializes in developing allogeneic, off-the-shelf CAR-T cell therapies for hematological malignancies. The company's primary focus is on innovative treatment solutions for patients suffering from T-cell cancers. Allotera aims to address the challenges associated with T-cell therapies by utilizing CRISPR/Cas9 gene editing. Through its robust clinical development, Allotera is dedicated to improving patient outcomes in areas with limited treatment options.
Predictive Intelligence
Strategic
ML-powered predictions for Allotera Therapeutics's next move
Saint LouisBiotechnologyHealth CareTherapeutics